QuidelOrtho Corporation (QDEL) – What Are Brokerages Saying About This Stock?

QuidelOrtho Corporation (NASDAQ:QDEL) has been given an average recommendation of “Reduce” by the six analysts that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $13.62.

Several equities research analysts have issued reports on QDEL shares. JPMorgan Chase & Co. boosted their price objective on shares of QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a research report on Wednesday, July 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a report on Thursday. Citigroup lifted their price target on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Jefferies Financial Group reissued a “hold” rating on shares of QuidelOrtho in a research note on Monday, June 29th. Finally, Wall Street Zen upgraded QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th.

QuidelOrtho Stock Down 7.2%

QDEL opened at $12.91 on Monday. The firm has a 50-day simple moving average of $12.88 and a two-hundred day simple moving average of $13.92. The company has a quick ratio of 0.76, a current ratio of 1.39 and a debt-to-equity ratio of 1.43. The company has a market capitalization of $885.24 million, a PE ratio of 10.30 and a beta of 0.79. QuidelOrtho has a 52 week low of $9.92 and a 52 week high of $35.58.

QuidelOrtho (NASDAQ:QDEL) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.18. QuidelOrtho had a positive return on equity of 4.88% and a negative net margin of 39.20%. The business had revenue of $630.90 million for the quarter, compared to the consensus estimate of $618.72 million. During the same period in the prior year, the business posted $0.12 earnings per share. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Analysts forecast that QuidelOrtho will post 0.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On QuidelOrtho

Several large investors have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC purchased a new position in shares of QuidelOrtho during the second quarter worth $53,000. IFP Advisors Inc lifted its position in shares of QuidelOrtho by 14,166.7% during the 2nd quarter. IFP Advisors Inc now owns 2,568 shares of the company’s stock worth $45,000 after buying an additional 2,550 shares during the last quarter. Squarepoint Ops LLC acquired a new position in QuidelOrtho in the second quarter valued at $1,493,000. Allworth Financial LP increased its position in QuidelOrtho by 161.3% during the second quarter. Allworth Financial LP now owns 3,209 shares of the company’s stock worth $56,000 after buying an additional 1,981 shares during the period. Finally, Corient Private Wealth LP acquired a new stake in QuidelOrtho during the 2nd quarter worth $363,000. 99.00% of the stock is currently owned by institutional investors and hedge funds.

About QuidelOrtho

QuidelOrtho Corporation (NASDAQ:QDEL) develops, manufactures and distributes diagnostic products used by healthcare providers, clinical laboratories and blood-processing organizations. The company’s offerings are designed to support the detection, diagnosis and monitoring of infectious diseases, cardiovascular conditions and other medical conditions.

Its product portfolio includes point-of-care testing systems, molecular diagnostic assays, immunoassays, clinical chemistry and immunodiagnostic platforms, as well as transfusion medicine products.